Abstract: A method and a device for the production of coloured animal or human foodstuffs and corresponding device, in particular, animal or human foodstuffs with two colours having clearly defined coloured regions. The above is achieved, whereby a product stream, preferably produced in an extruder, is divided into several independent part streams (depending on the number of colours) in a mixing run and each partial stream is mixed with a colour in a mixing chamber. The partial streams are mixed just before outlet nozzles on a nozzle plate, such that end products with clearly defined colour regions are produced after expansion and cutting.

Abstract: A method of manufacturing breadcrumbs, including the steps of forming a mixture, extruding the mixture to form loaves, surface drying the loaves in a first drying step, comminuting the loaves to form particles having a smaller size than the loaves, and further drying the particles in a second drying step to obtain the breadcrumbs.

Abstract: A system dynamically generates interfaces on demand during runtime execution of an application containing a plurality of objects. A user object generates a request for an interface of a service object. The service object, if the interface is not available, generates an adapter request and transmits same to an adapter manager. The adapter manager selects an interface adapter based on the adapter request from a library of interface adapters or aggregates a composite adapter and transmits the obtained interface adapter to the service object. The service object enables access from the user object based on the received interface adapter.

Abstract: This invention is directed to compounds of the formula (I): wherein one of R6, R7, R8 and R9 is and X, R1 to R12, m, n and o are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention is also directed to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: This invention relates to compounds of the formula wherein one of R6, R7 and R8 is and X, Y1 to Y4, R1 to R14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: The invention relates to a method and device for recovering therapeutic and diagnostic agents from the venous outflow of a tissue or organ. A method for recovering an agent includes inserting a catheter into a vascular outflow of a tissue or organ, occluding the flow of blood/fluid through the vascular outflow, and withdrawing blood/fluid in the vascular outflow into the catheter to recover at least a portion of the agent administered to the vascular inflow of the organ or tissue.

Abstract: This invention is concerned with compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R12, m, n and o are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: The present invention relates to compounds of formula (I) wherein wherein R1, R2, R3, R4, R5, R6 and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases (such as e.g. crown disease, inflammatory bowel disease, collitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function) and proliferative diseases.

Abstract: The present invention relates to compounds of formula (I) wherein wherein R1, R2, R3, R4, R5, R6 and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases (such as e.g. crown disease, inflammatory bowel disease, collitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function) and proliferative diseases.

Abstract: The invention relates to compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR ? and/or PPAR? agonists.

Abstract: The present invention relates to ANGPTL4 as biomarkers for PPARdelta activity, and to methods of diagnosing a disease linked to dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance, methods of monitoring the treatment of patients suffering from a disease linked to dysregulation of PPARdelta activity and methods of identifying compounds which modulate PPARdelta activity.

Abstract: This invention relates to compounds of the formula I: wherein one of R6, R7 and R8 is and R1 to R15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR ? and/or PPAR? agonists.

Abstract: Use of thiazolidinedione derivatives for the preparation of medicaments for inhibiting or reducing tumour growth or metastases, alone or in combination with an RXR agonist or well-known antitumour agent.

Abstract: A composition containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP.

Abstract: Cytokine CC-1 having the amino acid sequence according to SEQ ID No. 6 and its biologically active fragments and/or derivatives, in particular amidized, acetylized, phosphorylized and/or glycosylized derivatives.

Abstract: Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R8, A, A1 and n have the significance indicated in the specification.

Abstract: This invention relates to compounds of the formula wherein one of R6, R7 and R8 is and X, Y1 to Y4, R1 to R14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: This invention relates to compounds of the formula wherein one of R5, R6 and R7 is and X1, X2, Y1 to Y4, R1 to R13 and m and n are defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: There are presented compounds of the formula wherein R6 and R7 is R4 and R5 or R5 and R6 together with the carbon atoms to which they are attached, form a ring as defined in the description and X1, X2, Y1 to Y4, R1 to R13 and n are as specified in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.

Abstract: This invention relates to compounds of the formula wherein one of R6, R7 or R8 is and all enantiomers and pharmaceutically acceptable salts and/or esters thereof as well as pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.